Holdings
The Hartford Healthcare Fund
As of Jul 31, 2026, The Hartford Healthcare Fund reported 75 positions worth US$750M. Largest: Eli Lilly and Company, Johnson & Johnson and Merck & Company, Inc. What it bought and sold, with each filing.
Holdings
- Part of
- Hartford
- Positions
- 75
- Value as reported
- US$750M
- Holdings as of
- Jul 31, 2026
- Last filed
- Sep 29, 2026
| Company | Shares | Value as reported | % of portfolio | Change | As of |
|---|---|---|---|---|---|
| Eli Lilly and Company NYSE:LLY | 80,883 | US$92.9M | 12.0% | −13,636 | Jul 31, 2026 |
| Johnson & Johnson NYSE:JNJ | 203K | US$52.1M | 6.7% | +19,101 | Jul 31, 2026 |
| Merck & Company, Inc. NYSE:MRK | 356K | US$46.3M | 6.0% | −65,362 | Jul 31, 2026 |
| UnitedHealth Group Incorporated NYSE:UNH | 88,244 | US$36.6M | 4.7% | −20,768 | Jul 31, 2026 |
| AbbVie Inc. NYSE:ABBV | 130K | US$32.5M | 4.2% | +23,108 | Jul 31, 2026 |
| Elevance Health, Inc. NYSE:ELV | 61,615 | US$23.2M | 3.0% | +21,754 | Jul 31, 2026 |
| Intuitive Surgical, Inc. NASDAQ:ISRG | 62,861 | US$22.2M | 2.9% | +5,125 | Jul 31, 2026 |
| CVS Health Corporation NYSE:CVS | 210K | US$21.9M | 2.8% | −3,284 | Jul 31, 2026 |
| Vertex Pharmaceuticals Incorporated NASDAQ:VRTX | 42,701 | US$20.4M | 2.6% | +1,755 | Jul 31, 2026 |
| Danaher Corporation NYSE:DHR | 102K | US$19.9M | 2.6% | −7,473 | Jul 31, 2026 |
| Edwards Lifesciences Corporation NYSE:EW | 223K | US$19.2M | 2.5% | +643 | Jul 31, 2026 |
| Cencora, Inc. NYSE:COR | 61,017 | US$19M | 2.5% | +12,445 | Jul 31, 2026 |
| Regeneron Pharmaceuticals, Inc. NASDAQ:REGN | 20,444 | US$15.6M | 2.0% | +1,262 | Jul 31, 2026 |
| HCA Healthcare, Inc. NYSE:HCA | 36,047 | US$14.5M | 1.9% | +5,804 | Jul 31, 2026 |
| Boston Scientific Corporation NYSE:BSX | 310K | US$14.5M | 1.9% | +17,129 | Jul 31, 2026 |
| Abbott Laboratories NYSE:ABT | 133K | US$14.1M | 1.8% | −91,298 | Jul 31, 2026 |
| Thermo Fisher Scientific Inc NYSE:TMO | 21,279 | US$12.2M | 1.6% | −7,269 | Jul 31, 2026 |
| Agilent Technologies, Inc. NYSE:A | 85,848 | US$11.9M | 1.5% | +5,976 | Jul 31, 2026 |
| Amgen Inc. NASDAQ:AMGN | 27,841 | US$10.7M | 1.4% | New | Jul 31, 2026 |
| Biogen Inc. NASDAQ:BIIB | 51,870 | US$10.5M | 1.4% | +378 | Jul 31, 2026 |
| Stryker Corporation NYSE:SYK | 29,293 | US$9.54M | 1.2% | +2,312 | Jul 31, 2026 |
| GSK plc LSE:GSK | 347K | US$9.01M | 1.2% | −14,230 | Jul 31, 2026 |
| Medtronic plc. NYSE:MDT | 102K | US$8.67M | 1.1% | −4,484 | Jul 31, 2026 |
| Centene Corporation NYSE:CNC | 136K | US$8.48M | 1.1% | +91,407 | Jul 31, 2026 |
| DexCom, Inc. NASDAQ:DXCM | 93,874 | US$7.83M | 1.0% | −29,324 | Jul 31, 2026 |
| Incyte Corporation NASDAQ:INCY | 61,086 | US$7.3M | 0.95% | −841 | Jul 31, 2026 |
| Cardinal Health, Inc. NYSE:CAH | 30,813 | US$7.09M | 0.92% | −17,043 | Jul 31, 2026 |
| United Therapeutics Corporation NASDAQ:UTHR | 13,024 | US$6.74M | 0.87% | −2,073 | Jul 31, 2026 |
| STERIS plc (Ireland) NYSE:STE | 28,649 | US$6.54M | 0.85% | +161 | Jul 31, 2026 |
| Ucb S.A. EURONEXT:UCB | 23,685 | US$6.08M | 0.79% | +2,467 | Jul 31, 2026 |
| AstraZeneca PLC LSE:AZN | 35,800 | US$6.07M | 0.79% | +20,319 | Jul 31, 2026 |
| Ascendis Pharma A/S NASDAQ:ASND | 23,901 | US$5.83M | 0.75% | +999 | Jul 31, 2026 |
| Bristol-Myers Squibb Company NYSE:BMY | 88,181 | US$5.76M | 0.75% | No change | Jul 31, 2026 |
| Elanco Animal Health Incorporated NYSE:ELAN | 215K | US$5.67M | 0.73% | No change | Jul 31, 2026 |
| Cytokinetics, Incorporated NASDAQ:CYTK | 72,039 | US$5.56M | 0.72% | +9,720 | Jul 31, 2026 |
| Madrigal Pharmaceuticals, Inc. NASDAQ:MDGL | 11,677 | US$5.46M | 0.71% | +1,557 | Jul 31, 2026 |
| Ionis Pharmaceuticals, Inc. NASDAQ:IONS | 104K | US$5.39M | 0.70% | +25,150 | Jul 31, 2026 |
| Galderma Group AG SIX:GALD | 24,060 | US$5.24M | 0.68% | +3,659 | Jul 31, 2026 |
| Alnylam Pharmaceuticals, Inc. NASDAQ:ALNY | 24,864 | US$5.11M | 0.66% | +6,724 | Jul 31, 2026 |
| Revolution Medicines, Inc. NASDAQ:RVMD | 26,888 | US$5.04M | 0.65% | +2,951 | Jul 31, 2026 |
| Protagonist Therapeutics, Inc. NASDAQ:PTGX | 35,155 | US$4.8M | 0.62% | −5,533 | Jul 31, 2026 |
| PTC Therapeutics, Inc. NASDAQ:PTCT | 68,186 | US$4.64M | 0.60% | +15,637 | Jul 31, 2026 |
| Heartflow, Inc. NASDAQ:HTFL | 182K | US$4.59M | 0.59% | +34,208 | Jul 31, 2026 |
| BridgeBio Pharma, Inc. NASDAQ:BBIO | 57,222 | US$4.58M | 0.59% | +33,218 | Jul 31, 2026 |
| Arcus Biosciences, Inc. NYSE:RCUS | 160K | US$4.52M | 0.59% | No change | Jul 31, 2026 |
| Disc Medicine, Inc. NASDAQ:IRON | 55,907 | US$4.3M | 0.56% | No change | Jul 31, 2026 |
| argenx SE EURONEXT:ARGX | 4,871 | US$4.16M | 0.54% | −3,533 | Jul 31, 2026 |
| Encompass Health Corporation NYSE:EHC | 37,246 | US$4.14M | 0.54% | −10,550 | Jul 31, 2026 |
| Pharvaris N.V. NASDAQ:PHVS | 123K | US$4.03M | 0.52% | No change | Jul 31, 2026 |
| Kymera Therapeutics, Inc. NASDAQ:KYMR | 38,652 | US$4M | 0.52% | No change | Jul 31, 2026 |
| Celldex Therapeutics, Inc. NASDAQ:CLDX | 105K | US$3.99M | 0.52% | +12,809 | Jul 31, 2026 |
| Dianthus Therapeutics, Inc. NASDAQ:DNTH | 37,237 | US$3.98M | 0.52% | +2,183 | Jul 31, 2026 |
| Scholar Rock Holding Corporation NASDAQ:SRRK | 77,842 | US$3.68M | 0.48% | +7,968 | Jul 31, 2026 |
| Adaptive Biotechnologies Corporation NASDAQ:ADPT | 160K | US$3.61M | 0.47% | −58,313 | Jul 31, 2026 |
| Option Care Health, Inc. NASDAQ:OPCH | 151K | US$3.48M | 0.45% | +8,266 | Jul 31, 2026 |
| Zenas BioPharma, Inc. NASDAQ:ZBIO | 109K | US$3.42M | 0.44% | New | Jul 31, 2026 |
| Mirum Pharmaceuticals, Inc. NASDAQ:MIRM | 31,231 | US$3.31M | 0.43% | −6,739 | Jul 31, 2026 |
| Vaxcyte, Inc. NASDAQ:PCVX | 58,543 | US$3.17M | 0.41% | +15,573 | Jul 31, 2026 |
| Qiagen N.V. NYSE:QGEN | 74,691 | US$3.09M | 0.40% | −9,478 | Jul 31, 2026 |
| Immunome, Inc. NASDAQ:IMNM | 136K | US$3.09M | 0.40% | +18,697 | Jul 31, 2026 |
| CG Oncology, Inc. NASDAQ:CGON | 40,863 | US$2.91M | 0.38% | +27,158 | Jul 31, 2026 |
| Trevi Therapeutics, Inc. NASDAQ:TRVI | 156K | US$2.84M | 0.37% | −25,006 | Jul 31, 2026 |
| Inspire Medical Systems, Inc. NYSE:INSP | 51,992 | US$2.61M | 0.34% | No change | Jul 31, 2026 |
| Stoke Therapeutics, Inc. NASDAQ:STOK | 89,171 | US$2.57M | 0.33% | +12,266 | Jul 31, 2026 |
| Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class A SSE:600276 | 305K | US$2.32M | 0.30% | −26,506 | Jul 31, 2026 |
| Kailera Therapeutics, Inc. NASDAQ:KLRA | 133K | US$2.26M | 0.29% | −54,842 | Jul 31, 2026 |
| Moderna, Inc. NASDAQ:MRNA | 40,629 | US$2.23M | 0.29% | New | Jul 31, 2026 |
| Definium Therapeutics, Inc. NASDAQ:DFTX | 49,500 | US$2.15M | 0.28% | New | Jul 31, 2026 |
| Dyne Therapeutics, Inc. NASDAQ:DYN | 85,300 | US$2.15M | 0.28% | New | Jul 31, 2026 |
| Genfleet Therapeutics (Shanghai), Inc. Class H HKEX:2595 | 584K | US$2.06M | 0.27% | No change | Jul 31, 2026 |
| Alignment Healthcare, Inc. NASDAQ:ALHC | 131K | US$1.94M | 0.25% | −4,496 | Jul 31, 2026 |
| ICON plc NASDAQ:ICLR | 11,852 | US$1.94M | 0.25% | −21,818 | Jul 31, 2026 |
| Avalyn Pharma Inc. NASDAQ:AVLN | 17,700 | US$510K | 0.07% | New | Jul 31, 2026 |
| Alebund Pharmaceuticals (Jiangsu) Limited Class H HKEX:9637 | 85,600 | US$297K | 0.04% | New | Jul 31, 2026 |
| Alamar Biosciences, Inc. NASDAQ:ALMR | 9,100 | US$231K | 0.03% | No change | Jul 31, 2026 |